Bristol Myers Squibb's first quarter 2026 revenue grew 3% driven by a 12% increase in its Growth Portfolio.

Bristol Myers Squibb reported first quarter 2026 revenue of $11.5 billion, an increase of 3% year-over-year, while non-GAAP EPS declined 12% to $1.58. The company reaffirmed its full-year 2026 guidance, noting that results are trending toward the upper end of the range.

Key Highlights

• The company's Growth Portfolio revenues increased 12% to $6.2 billion, driven by strong performance from drugs including Camzyos, Breyanzi, and Reblozyl.
• Revenues from the Legacy Portfolio decreased 6% to $5.3 billion, primarily due to generic competition for Revlimid, which saw sales decline 63%.
• Bristol Myers Squibb reaffirmed its full-year 2026 guidance for revenue of $46.0 billion to $47.5 billion and non-GAAP EPS of $6.05 to $6.35.